Logo

SeeTreat partners with Lumonus

Lumonus and SeeTreat are pleased to announce their partnership to improve personalisation and precision in radiotherapy treatment in the USA in 2024.

Combining Lumonus AI Product with SeeTreat's software solutions means ALL patients can be assured of receiving radiotherapy to the right place at the right time despite changes in tumour size or shape and anatomy over the course of treatment. Our combined software solutions are designed to be user centric, efficient and accessible to all. Our teams are excited to be joining forces to innovate for the benefit of millions of cancer patients each year.

Related news

  • C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
    Dr Trang Nguyen
    Dr Trang Nguyen29 September 2026

    C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic

    C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.

    Read more
  • ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
    Dr Sean Pollock
    Dr Sean Pollock17 September 2026

    ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy

    SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."

    Read more
  • SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
    Antonia Dalton
    Antonia Dalton19 May 2026

    SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA

    SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.

    Read more